Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bicifadine

Drug Profile

Bicifadine

Alternative Names: CL 220075; DOV 220075

Latest Information Update: 02 Mar 2009

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Wyeth
  • Developer DOV Pharmaceutical; XTL Biopharmaceuticals
  • Class Heterocyclic bicyclo compounds; Non-opioid analgesics; Small molecules
  • Mechanism of Action Adrenergic receptor antagonists; Dopamine uptake inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Diabetic neuropathies; Osteoarthritis; Pain

Most Recent Events

  • 18 Nov 2008 Top-line efficacy data from a phase IIb trial in Diabetic neuropathic pain released by XTL Biopharmaceuticals
  • 09 Oct 2008 XTL Biopharmaceuticals completes a phase IIb trial in Diabetic neuropathies in US, Germany, Israel and India
  • 30 Jun 2008 XTL completes randomisation in its phase IIb trial for diabetic neuropathic pain in the US, Germany, Israel & India
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top